Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (10512)
All Articles published online
|
Publishing Process of This Article
|
Apr 28, 2020 (publication date) through Nov 3, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Piñero F, Silva M, Iavarone M. Sequencing of systemic treatment for hepatocellular carcinoma: Second line competitors. World J Gastroenterol 2020; 26(16): 1888-1900 [PMID: 32390700 DOI: 10.3748/wjg.v26.i16.1888] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v26/i16/1888.htm |
| Number | Citing Articles |
| 1 |
Maria Cerreto, Ferdinando Cardone, Lucia Cerrito, Leonardo Stella, Francesco Santopaolo, Maria Pallozzi, Antonio Gasbarrini, Francesca Romana Ponziani. The New Era of Systemic Treatment for Hepatocellular Carcinoma: From the First Line to the Optimal Sequence. Current Oncology 2023; 30(10): 8774 doi: 10.3390/curroncol30100633
|
| 2 |
Young Mi Hong, Ki Tae Yoon, Tae Ho Hwang, Mong Cho. Pretreatment peripheral neutrophils, lymphocytes and monocytes predict long-term survival in hepatocellular carcinoma. BMC Cancer 2020; 20(1) doi: 10.1186/s12885-020-07105-8
|
| 3 |
Taito Fukushima, Manabu Morimoto, Makoto Ueno, Kousuke Kubota, Haruki Uojima, Hisashi Hidaka, Makoto Chuma, Kazushi Numata, Kota Tsuruya, Shunji Hirose, Tatehiro Kagawa, Nobuhiro Hattori, Tsunamasa Watanabe, Kotaro Matsunaga, Kouji Yamamoto, Katsuaki Tanaka, Shin Maeda. Comparative study between sorafenib and lenvatinib as the first‐line therapy in the sequential treatment of unresectable hepatocellular carcinoma in a real‐world setting. JGH Open 2022; 6(1): 29 doi: 10.1002/jgh3.12691
|
| 4 |
Alexandru Blidisel, Iasmina Marcovici, Dorina Coricovac, Florin Hut, Cristina Adriana Dehelean, Octavian Marius Cretu. Experimental Models of Hepatocellular Carcinoma—A Preclinical Perspective. Cancers 2021; 13(15): 3651 doi: 10.3390/cancers13153651
|
| 5 |
Piera Federico, Emilio Francesco Giunta, Andrea Tufo, Francesco Tovoli, Angelica Petrillo, Bruno Daniele. Resistance to Antiangiogenic Therapy in Hepatocellular Carcinoma: From Molecular Mechanisms to Clinical Impact. Cancers 2022; 14(24): 6245 doi: 10.3390/cancers14246245
|
| 6 |
Limin An, Haotian Liao, Kefei Yuan. Efficacy and Safety of Second-line Treatments in Patients with Advanced Hepatocellular Carcinoma after Sorafenib Failure: A Meta-analysis. Journal of Clinical and Translational Hepatology 2021; 0(000): 000 doi: 10.14218/JCTH.2021.00054
|
| 7 |
Amit G. Singal, Saurabh P. Nagar, Abby Hitchens, Keith L. Davis, Shrividya Iyer. Real‐world effectiveness of lenvatinib monotherapy in previously treated unresectable hepatocellular carcinoma in US clinical practice. Cancer Reports 2023; 6(1) doi: 10.1002/cnr2.1679
|
| 8 |
Ignacio Ventura, Lorena Sanchiz, María Ester Legidos-García, María Teresa Murillo-Llorente, Marcelino Pérez-Bermejo. Atezolizumab and Bevacizumab Combination Therapy in the Treatment of Advanced Hepatocellular Cancer. Cancers 2023; 16(1): 197 doi: 10.3390/cancers16010197
|
| 9 |
Federico Piñero, Marcos Thompson, Juan Ignacio Marín, Marcelo Silva. Lenvatinib as first-line therapy for recurrent hepatocellular carcinoma after liver transplantation: Is the current evidence applicable to these patients?. World Journal of Transplantation 2020; 10(11): 297-306 doi: 10.5500/wjt.v10.i11.297
|
| 10 |
Federico Piñero, Ezequiel Mauro, Paola Casciato, Alejandro Forner. From evidence to clinical practice: Bridging the gap of new liver cancer therapies in Latin America.. Annals of Hepatology 2024; 29(3): 101185 doi: 10.1016/j.aohep.2023.101185
|
| 11 |
Lucia Cerrito, Francesco Santopaolo, Flavia Monti, Maurizio Pompili, Antonio Gasbarrini, Francesca Romana Ponziani. Advances in pharmacotherapeutics for hepatocellular carcinoma. Expert Opinion on Pharmacotherapy 2021; 22(10): 1343 doi: 10.1080/14656566.2021.1892074
|
| 12 |
Jonathan H. Joachim, Kosha J. Mehta. Hepcidin in hepatocellular carcinoma. British Journal of Cancer 2022; 127(2): 185 doi: 10.1038/s41416-022-01753-2
|
| 13 |
Xu-Wang Pan, Jin-Song Huang, Shou-Rong Liu, Yi-Dan Shao, Jian-Jun Xi, Ruo-Yu He, Ting-Ting Shi, Rang-Xiao Zhuang, Jian-Feng Bao. Evaluation of the liver targeting and anti‑liver cancer activity of artesunate‑loaded and glycyrrhetinic acid‑coated nanoparticles. Experimental and Therapeutic Medicine 2023; 26(5) doi: 10.3892/etm.2023.12215
|
| 14 |
Zhong‐Ming Bao, Dan Yao, Xu Qian, Hua‐Guo Zhang, Ming Yang, Yun‐Hu Guo, Lei Qin. Activating transcription factor 2 promotes the progression of hepatocellular carcinoma by inducing the activation of the WHSC1‐mediated TOP2A/PI3K/AKT axis. The Kaohsiung Journal of Medical Sciences 2022; 38(7): 662 doi: 10.1002/kjm2.12536
|
| 15 |
P. Baby Shakila, Muruganantham Bharathi, Nouf M. Alyami, Sulaiman Ali Alharbi, Samer Hasan Hussein-Al-Ali, Saravana Kumar Jaganathan, Palanisamy Arulselvan. Innovative Nickel Oxide-Pluronic F127-Escin Hybrids: Synthesis, Characterization, and Dual Bioactivity Against Bacteria and Cancer Cells. Journal of Inorganic and Organometallic Polymers and Materials 2024; doi: 10.1007/s10904-024-03347-2
|
| 16 |
Maria Guarino, Alessandro Cucchetti, Giuseppina Pontillo, Fabio Farinati, Francesca Benevento, Gian Ludovico Rapaccini, Maria Di Marco, Eugenio Caturelli, Marco Zoli, Sacco Rodolfo, Giuseppe Cabibbo, Fabio Marra, Andrea Mega, Antonio Gasbarrini, Gianluca Svegliati‐Baroni, Francesco Giuseppe Foschi, Gabriele Missale, Alberto Masotto, Gerardo Nardone, Giovanni Raimondo, Francesco Azzaroli, Gianpaolo Vidili, Filippo Oliveri, Franco Trevisani, Edoardo G. Giannini, Filomena Morisco. Pattern of macrovascular invasion in hepatocellular carcinoma. European Journal of Clinical Investigation 2021; 51(7) doi: 10.1111/eci.13542
|
| 17 |
He-nan Qin, Zhen Ning, Rui Sun, Chen-xing Jin, Xin Guo, A-man Wang, Ji-wei Liu. Lenvatinib as second-line treatment in patients with unresectable hepatocellular carcinoma: A retrospective analysis. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.1003426
|
| 18 |
Gopika Chandrababu, Sunil Kumar Sah, Ayana R. Kumar, Sabitha M, Lekshmi R. Nath. Green Synthesized Nanoparticles as a Plausible Therapeutic Strategy
Against Hepatocellular Carcinoma: An Update on its Preclinical and
Clinical Relevance. Recent Patents on Anti-Cancer Drug Discovery 2023; 18(3): 268 doi: 10.2174/1574892817666220523124437
|
| 19 |
Hui-Qi Liu, Li-Xin Sun, Long Yu, Jun Liu, Li-Chao Sun, Zhi-Hua Yang, Xiong Shu, Yu-Liang Ran. HSP90, as a functional target antigen of a mAb 11C9, promotes stemness and tumor progression in hepatocellular carcinoma. Stem Cell Research & Therapy 2023; 14(1) doi: 10.1186/s13287-023-03453-x
|
| 20 |
Ester Gonzalez-Sanchez, Javier Vaquero, Maite G. Férnandez-Barrena, Juan José Lasarte, Matías A. Avila, Pablo Sarobe, María Reig, Mariona Calvo, Isabel Fabregat. The TGF-β Pathway: A Pharmacological Target in Hepatocellular Carcinoma?. Cancers 2021; 13(13): 3248 doi: 10.3390/cancers13133248
|
| 21 |
|